AzTrials
AzTrials

Mobility ImpairmentPhase 2HEALTHNCT07214896

Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings

A Phase 2 study testing Skin Cell Dip, Stem Cell Dip and Wage Token Distribution in people with Mobility Impairment and Clinical Workflow Optimization, run by Truway Health, Inc. at 4 sites in 3 countries.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and intake workflows. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
What is being tested?
Skin Cell Dip, Stem Cell Dip and Wage Token Distribution
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
4 sitesin 3 countries
Study dates
6 Oct 2025to 6 Oct 2031
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Age 18-75 years
  • Able to provide informed consent
  • Facility staff, clinical auditors, ESG observers, or coalition stakeholders
  • Willing to interact with humanoid robotics in clinical workflows
  • Available for biometric feedback and observational logging over 90 days

Who cannot join

  • Cognitive impairment preventing informed consent
  • Active infectious disease requiring isolation
  • Prior adverse reaction to biotech-enhanced robotics
  • Involvement in conflicting clinical trials
  • Inability to comply with protocol procedures or coalition transparency requirements

Trial locations and contacts

4 sites in 3 countries. Contact the study team or a site near you to ask about taking part.

4 sites in 3 countries

United States2 sites

  • Coalition Retrofit Clinic - Austin, TX

    Austin, Texas, 73301

  • Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016

    New York, New York, 10016

Other trials in United States

Germany1 site

  • ESG Compliance Lab

    Frankfurt, 60435

Other trials in Germany

Japan1 site

  • Public Interface Pilot

    Tokyo, 100-1000

Other trials in Japan

About this study

Official title: HEALTH: Humanoid Evaluation and Learning Trial in Coalition-Aligned Healthcare Settings

This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and intake workflows. Humanoid units are enhanced via biotech integration and compensated through blockchain-based wage tokens. Outcomes will inform coalition governance, wage calibration, and metro-scale deployment strategies.

Read the detailed description

The HEALTH trial (Humanoid Evaluation and Learning Trial in Healthcare) is a coalition-aligned clinical study designed to assess the deployment of humanoid robotics in real-world care environments. Conducted across metro facilities in New York, Austin, Frankfurt, and Tokyo, the trial evaluates robotic performance in patient intake, sanitation, mobility assistance, and ESG-linked operations.

Humanoid units are enhanced through biotech integration, including skin cell regeneration dips and stem cell neural augmentation. Each unit is tracked via biometric audit scoring across five dimensions: motor function, cognitive response, ESG compliance, biotech retention, and human interaction. Scores are notarized via SHA-256 and published to the coalition dashboard.

Wage tokens (HumanoidWage, HMW) are minted based on performance thresholds and distributed through smart contracts to deployed units. FX arbitrage across Tokyo and Frankfurt informs reinvestment logic and 1031 exchange-backed yield farming pools. DAO voting governs deployment, wage calibration, and protocol expansion.

This trial aims to establish scalable, transparent frameworks for humanoid integration in healthcare, anchored in coalition governance, public oversight, and metro-ready infrastructure.

Being tested
Skin Cell Dip, Stem Cell Dip, Wage Token Distribution, ESG Compliance Monitoring, Operational protocol
Keywords
Humanoid robotics in healthcare, Clinical deployment of humanoid robots, Biometric audit scoring, ESG compliance in clinical settings, Stem cell integration in robotics, Skin cell regeneration for humanoid units, Blockchain wage token for robotics, FX arbitrage in healthcare robotics, Coalition-aligned clinical trial, Metro-scale robotics deployment, Patient mobility assistance, Sanitation protocol automation, DAO-governed healthcare infrastructure, 1031 exchange yield farming in clinical care, Adaptive learning in humanoid systems, Public oversight of robotic healthcare trials

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Skin Cell DipBiological

    Lab-grown keratinocyte dip applied to humanoid units to improve tactile sensitivity and surface regeneration.

  • Stem Cell DipBiological

    iPSC-derived neuroblast dip applied to humanoid units to enhance neural responsiveness and adaptive learning.

  • Wage Token DistributionOther

    Also called Blockchain-based compensation

    HumanoidWage (HMW) tokens minted and distributed based on biometric audit scores and ESG task completion.

  • ESG Compliance Monitoring, Operational protocolBehavioural

    Real-time tracking of energy usage, sanitation cycles, and carbon offset metrics via coalition dashboard.

Study groups in NCT07214896
Study groupRoleWhat they receive
New York Facility - Skin Cell DeploymentExperimentalHumanoid units deployed in patient intake and sanitation roles. Enhanced with keratinocyte-based skin cell dips to improve tactile sensitivity and surface regeneration. Assigned Roles: Intake assistant, sanitation technician Biometric Focus: Motor function, ESG compliance
Receives: Biological: Skin Cell Dip
Austin Facility - Stem Cell Cognitive EnhancementExperimentalHumanoid units deployed in mobility and R\&D support roles. Enhanced with iPSC-derived stem cell dips targeting neural responsiveness and adaptive learning. Assigned Roles: Mobility assistant, lab technician Biometric Focus: Cognitive response, biotech retention
Receives: Biological: Stem Cell Dip
Frankfurt Facility - ESG OptimizationExperimentalHumanoid units deployed in ESG-linked sanitation and logistics roles. Monitored for energy usage, carbon offset, and protocol adherence. Assigned Roles: ESG sanitation, logistics handler Biometric Focus: ESG compliance, human interaction
Receives: Behavioral: ESG Compliance Monitoring, Operational protocol
Tokyo Facility - Wage Token CalibrationExperimentalHumanoid units deployed in public interface and intake roles. Wage tokens minted based on biometric audit scores and task completion. Assigned Roles: Receptionist, intake coordinator Biometric Focus: Wage token distribution, interaction scoring
Receives: Other: Wage Token Distribution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Biometric Audit Score ≥85 Across Five Performance Dimensions

    This outcome assesses the performance of humanoid robotics units deployed in coalition-aligned healthcare settings. Each unit is scored across five biometric dimensions: motor function, cognitive response, ESG compliance, biotech integration, and human interaction. Scores are notarized via SHA-256 and published to the coalition dashboard. Units achieving a composite score ≥85 are eligible for wage token bonuses, dip protocol expansion, and DAO-backed facility scaling.

    Measured: Measured at Day 30 Post-Deployment

Secondary outcomes (3)

  1. ESG Audit Compliance Score ≥90

    Measured at Day 60 Post-Deployment

    Measured: Humanoid units are evaluated for ESG-linked performance including energy usage, sanitation protocol adherence, and carbon offset metrics. Scores are published to the coalition dashboard and notarized via SHA-256. Units scoring ≥90 contribute to DAO-backe

  2. Wage Token Distribution Volume per Unit

    Tracks the volume of HumanoidWage (HMW) tokens minted and distributed to each humanoid unit based on biometric audit scores and task completion. Token flow is logged on-chain and used to calibrate coalition wage pools and reinvestment logic.

    Measured: Continuous Monitoring Over 90 Days

  3. Clinical Workflow Efficiency Increase ≥15%

    Assesses improvements in patient intake speed, sanitation cycle time, and mobility assistance throughput across facilities. Benchmarked against pre-deployment baselines and validated by coalition auditors.

    Measured: Measured at Day 90 Post-Deployment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2025
  2. Study start6 Oct 2025
  3. Primary completion6 Oct 2031 (estimated)
  4. Study completion6 Oct 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
Humanoid robotics units are deployed across multiple metro healthcare facilities in parallel. Each facility represents a distinct intervention arm with tailored deployment protocols, biotech integration (skin/stem cell dips), and wage token logic. Outcomes are measured independently across arms using biometric audit scoring and ESG compliance metrics.
Masking
None (open label)
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07214896
Sponsor's protocol ID
TRU-HUM-CLIN-2025-PRS
Acronym
HEALTH
Status last verified
Nov 2026
First submitted
8 Oct 2025
Last updated
5 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data (IPD) collected during this trial-including biometric audit scores, ESG compliance metrics, and wage token distribution logs-will be shared with qualified researchers upon request. Data will be de-identified, SHA-256 notarized, and made available through Truway Health's coalition dashboard and secure data access portal. Access will require submission of a research proposal, DAO approval, and compliance with coalition transparency protocols.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Skin Cell Dip, Stem Cell Dip and Wage Token Distribution in people with Mobility Impairment and Clinical Workflow Optimization, run by Truway Health, Inc. at 4 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States, Germany, Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Biometric Audit Score ≥85 Across Five Performance Dimensions (time frame: Measured at Day 30 Post-Deployment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07214896.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in